<DOC>
	<DOCNO>NCT01586845</DOCNO>
	<brief_summary>The purpose study demonstrate efficacy safety voclosporin administer orally twice daily prevention acute allograft rejection recipient kidney transplant .</brief_summary>
	<brief_title>Safety Efficacy Study Voclosporin Tacrolimus Transplantation</brief_title>
	<detailed_description>This phase III , randomize , multicentre , open-label , concentration-controlled study subject undergo first second renal transplant , induction immunosuppression IL-2 receptor antibody ( basiliximab ) , mycophenolate mofetil steroid . The primary endpoint ass non-inferiority efficacy failure end Month 12 randomization .</detailed_description>
	<mesh_term>Tacrolimus</mesh_term>
	<mesh_term>Cyclosporine</mesh_term>
	<criteria>Males female age 1865 year inclusive time screen . Recipients first second decease donor live donor renal transplant . Subjects presently receive immunosuppression previously fail transplant . Females pregnant nursing planning become pregnant course study , 3 month last dose study medication . Sexuallyactive woman childbearing potential ( include &lt; 1 year postmenopausal ) sexuallyactive men practice highly effective method birth control . Subjects receive HLA identical living relate transplant . Subjects wth positive Tcell lymphocytotoxic cross match , positive flow T B cell cross match . Subjects undergoing primary transplant current PRA ( CPRA ) ≥ 25 % . Subjects experience graft loss within 1 year transplant . Subjects receive kidney ABO incompatible donor . Subjects receive kidney decease donor positive HIV , HBV , HCV tuberculosis . Subjects receive kidney nonheart beat donor . Subjects receive pair ( en bloc pair ) kidney transplant . Transplantation multiple graft ( e.g . kidney pancreas ) . Subjects receive kidney cold ischemia time &gt; 30 hour . Subjects receive transplant organ kidney . Recipients bone marrow stem cell transplant . Any systemic infection require continued therapy time entry study . ( Prophylaxis CMV and/or PCP infection permit ) . Subjects positive result follow serological test : HIV I Ab , hepatitis B virus ( HBV ) surface antigen ( HBsAg ) , antihepatitis B core antibody ( HBcAb ) , antihepatitis C virus antibody ( HCV Ab ) . Negative result serological test must document within 12 month prior randomization . Subjects active tuberculosis ( Tb ) require treatment within last 3 year . Subjects know positive purify protein derivative ( PPD ) test eligible unless complete treatment latent Tb negative chest Xray time enrollment . PPD test must do within last 12 month , positive result define ≥ 10 mm induration , Heaf score &gt; 1 nonBacille CalmetteGuérin ( BCG ) immunize subject , &gt; 2 BCG immunized subject . Subjects current malignancy history malignancy within 5 year history lymphoma time . Subjects enrol history squamous basal cell carcinoma surgically excise remove curettage electrodessication .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>January 2014</verification_date>
	<keyword>Randomized Controlled Trials</keyword>
	<keyword>Immunosuppression</keyword>
	<keyword>Adult</keyword>
	<keyword>Kidney Transplantation</keyword>
	<keyword>Treatment Outcome</keyword>
</DOC>